SciBase introduces Nevisense View – integrating images in the fight against malignant melanoma

With its new instrument, Nevisense View, SciBase combines its patented electrical impedance spectroscopy (EIS) for early detection of malignant melanoma with visual information from digital dermascopy, creating a complete instrument that can both improve and simplify the diagnostic process.  

Malignant melanoma is the most threatening form of skin cancer and is behind 75 percent of all skin cancer deaths. The key to successful treatment of malignant melanoma is early discovery, since this aggressive form of cancer can quickly spread throughout the body. The cancer is often difficult to detect, and digital dermascopy is one of the methods used for detection. This method is based on visual evaluations of skin lesions using a dermascope, while hard-to-diagnose cases often make use of short term digital dermoscopy imaging (SDDI) to compare pictures of lesions that have changed over time.

SciBase is now integrating the digital dermascopy method into its new product and combining it with EIS technology, which uses electrical impulses to detect abnormal cell structures that could be a sign of malignant melanoma. Furthermore, SciBase’s new instrument also simplifies the process for performing skin examinations since all information from the exam is saved in the same instrument. The ability to track the changes of a suspicious lesion, both using EIS values and images, helps prevent both the unnecessary removal of benign tissue and helps avoid malignant melanoma going undetected during an examination.

“According to a new study, conducted by researchers from Melanoma Institute of Australia and Royal Prince Alfred Hospital in Sydney, the use of EIS can reduce the number of cases that need to be followed up using SDDI by almost half, and may also allow for early detection of malignant melanoma three months earlier than traditional methods,” says Simon Grant, CEO of SciBase.  

“Being able to combine these two methods into one product and present it in conjunction with a study that supports our method at the World Congress on Cancers of the Skin in Vienna on August 31 is of course a milestone in the company’s history,” says Simon.

Nevisense View simplifies caregivers’ work by offering the following functions:

• Wireless transfer of images to Nevisense
• Combination of EIS, image and patient information as a PDF report for full documentation of the examination.
• Easy-to-use follow-up functions, such as a shared screen for being able to compare lesions over time. 

Nevisense View will be available in Sweden and in SciBase’s other markets in November. More information about the study can be found here: Swedish Nevisense can reduce follow up visits by half for difficult-to-diagnose skin changes in melanoma detection

For more information, please contact:

Simon Grant, CEO
Phone: +46 72 887 43 99
Email: simon.grant@scibase.com

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on August 31, 2016.

About Skin Cancer
Skin cancer is one of the most common cancers in the world, accounting for nearly half of all cancers. It has been estimated that nearly half of all Americans who live to the age of 65 will develop skin cancer at least once. Malignant melanoma is the most fatal form of skin cancer causing the majority (75%) of deaths related to skin cancer. Worldwide, doctors diagnose about 230,000 new cases of melanoma yearly.

About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and is awaiting FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. SciBase is listed on Nasdaq First North (“SCIB”). Avanza is the certified advisor. Further information is available on www.scibase.com. 

Tags: